BYD Launched BAO 5 under Its New Brand FANGCHENGBAO and the DMO Technology
4.9.2023 12:43:00 EEST | Business Wire | Press release
BYD, the world’s leading manufacturer of new energy vehicles and power batteries, introduced FANGCHENGBAO, its new professional personalized sub-brand, as well as its sophisticated technology: the Dual Mode Off-road (DMO) Super Hybrid Platform. The first model of the new brand - BAO 5, a super hybrid off-road SUV harnessing the DMO technology was launched during the event as well as a concept car BAO 8 and BAO 3.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230817807422/en/
Wang Chuanfu, the Chairman and President of BYD (Photo: Business Wire)
Wang Chuanfu, the Chairman and President of BYD, said at the launch event that FANGCHENGBAO aspires to redefine vehicular experience by offering an unparalleled blend of professionalism and personalization to global users, driving a profound "revolution" in the NEV landscape, transforming cars into unique, tailor-made assets for every individual.
The Brand: A great leap in New Energy Vehicle Sector
The brand name FANGCHENGBAO, derived from Chinese phonetics, symbolizes a blend of precision ("FANGCHENG" for "formula") and agility ("BAO" for "leopard"), introducing a series of specialized technologies, including the DMO Super Hybrid Off-Road Platform, which is also inaugurated at the event.
FANGCHENGBAO envisions the confluence of state-of-the-art new energy technologies and diverse users' preferences will unlock unprecedented user experience: whether journeying through the vast wilderness, speeding on a racetrack, navigating through bustling cityscapes, or cruising on highways; whether seeking occasional exhilaration or traversing daily commutes, an exclusive driving experience for every scenario is now within reach.
To meet this end, FANGCHENGBAO will integrate BYD's apex technologies, forward-looking designing ethos, and the vertically integrated supply chain system, in order to enrich every vehicle with distinctive tailor-made possibilities.
FANGCHENGBAO symbolizes the fusion of new energy and boundless possibilities, turning every individual's dreams into tangible reality.
The DMO Technology: Unleashing the Might of Electricity for Individual Empowerment
At the event, BYD unveiled the innovative DMO Super Hybrid Off-Road Platform, signaling a significant pivot from traditional gasoline engines. This platform powers the FANGCHENGBAO vehicles, promising a transformative off-road experience while championing energy efficiency, and empowering every user with pinnacle technology.
The DMO combines BYD's Revolutionary Non-Load-Bearing Frame Designed for Hybrids with a specialized off-road hybrid architecture. This integration taps into BYD's expertise in high-performance chassis, intelligent electric four-wheel drive, and off-road powertrains. As a result, DMO strikes an unparalleled balance between vehicle safety, powerful off-roading, and energy consumption.
Instead of traditional modifications that add weight and increase rollover risks, the DMO innovatively fuses the Blade Battery and high-strength steel frame, evolving to the Cell to Chassis (CTC) technology. This not only ensures battery safety during extreme off-road scenarios but also significantly boosts overall vehicle safety.
The platform also boasts features like the longitudinal EHS electric hybrid system and an industry-first off-road rear-drive powertrain, as well as the Xiaoyun longitudinal high-performance engine, delivering a formidable system power of more than 500kW and an unmatched traction of 32,000N. Moreover, DMO vehicles utilize intelligent torque control technology to minimize the turning radius to just 3.4 meters. Also thanks to its powerful drive and precise electronic control, users can effortlessly navigate through swampy terrains, rugged mountains, gravelly slopes, and many other extreme terrains with the DMO. Equipped with three Differential Locks, drivers can switch to low-speed gear, which is designed for off-road scenario, with a push on the button.
Building on this innovative architecture, DMO incorporates a double-wishbone independent suspension at both ends, which, when paired with DiSus-P Hydraulic Body Control System, assures SUV-like comfort even in challenging terrains. The platform achieves 35% fuel savings compared to gasoline-powered off-road vehicles.
DMO stands out as a predominantly electric-driven, professional-grade off-road platform. It represents the culmination of over twenty years of BYD's cutting-edge technological evolution and insights from the experience gleaned from millions of BYD PHEVs. This platform transcends the conventional and substantially amplifies the capabilities of electric mobility. With its vast technical prowess, the DMO surmounts challenges that new energy vehicles typically encountered across scenarios, recalibrating the paradigm for off-road vehicular design and functionality.
Looking ahead, FANGCHENGBAO is set to venture into domains such as off-road SUVs and sports cars, where traditional gasoline vehicles predominate, starting from models with the DMO platform.
The New Models: Pioneers With Leading Technology and Unique Product Offerings
Three FANGCHENGBAO's models offer a powerful product lineup, catering to a range of individual preferences, demonstrating its robust product matrix and its dedication to professionalism and individuality.
The BAO 5, positioned as a super hybrid off-road SUV, is equipped with key technologies like DMO and DiSus-P Hydraulic body control system. Its design seamlessly combines industrial aesthetics with robust power, delivering unparalleled stability and safety for users.
As a brand emphasizing customization, FANGCHENGBAO offers the BAO 5 a variety of front-face structures that can be seamlessly integrated or adjusted. It provides a flexible foundation tailored to each user's unique modification preferences.
The BAO 8 concept car, named SUPER 8, unveils the brand's futuristic vision for off-road SUVs. Inspired by sci-fi battlefields, this design ensures robust integration and enhanced protection, inspiring driver confidence. Furthermore, preliminary details about the BAO 3 were revealed, hinting at a trendy model geared towards diverse audiences with a playful spirit.
To ensure consistent service and experience quality, FANGCHENGBAO will adopt a Direct-to-Consumer (DTC) model in the initial phase in the Chinese market, planning to reach 60 cities by 2024. It is also announced that the BAO 5 will have its first offline debut at the Chengdu Motor Show, starting August 25th.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230817807422/en/
Contact information
Asia-Pacific: Liya Huang, pr@byd.com tel: +86-755-8988-8888-69666
Europe: Penny Peng, PressEU@byd.com tel: +31-102070888
North America: Frank Girardot, frank.girardot@byd.com tel: +1 213 245 6503
Latin America: José Miranda, jose.miranda@byd.com
tel: +56 9 96443906
Brazil: Pablo Toledo, pablo.toledo@byd.com tel: +19 3514 2554
Middle East and Africa: Nikki Li, li.namin@byd.com tel: +86-18938862670
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
